Molecular Imaging of Bone Metastases Using Tumor-Targeted Tracers Publisher Pubmed



Karamzadeziarati N¹ ; Manafifarid R¹ ; Ataeinia B² ; Langsteger W³ ; Pirich C⁴ ; Mottaghy FM^{5, 6} ; Beheshti M^{4, 5} Show Affiliations
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging Published:2019

Abstract

Bone metastasis is a disastrous manifestation of most malignancies, especially in breast, prostate and lung cancers. Since asymptomatic bone metastases are not uncommon, early detection, precise assessment, and localization of them are very important. Various imaging modalities have been employed in the setting of diagnosis of bone metastasis, from plain radiography and bone scintigraphy to SPECT, SPECT/CT, PET/CT, MRI. However, each modality showed its own limitation providing accurate diagnostic performance. In this regard, various tumor-targeted radiotracers have been introduced for molecular imaging of bone metastases using modern hybrid modalities. In this article we review the strength of different cancer-specific radiopharmaceuticals in the detection of bone metastases. As shown in the literature, among various tumor-targeted tracers, 68Ga DOTA-conjugated-peptides, 68Ga PSMA, 18F DOPA, 18F galacto-RGD integrin, 18F FDG, 11C/18F acetate, 11C/18F choline, 111In octreotide, 123/131I MIBG, 99mTc MIBI, and 201Tl have acceptable capabilities in detecting bone metastases depending on the cancer type. However, different study designs and gold standards among reviewed articles should be taken into consideration. © 2019 Edizioni Minerva Medica.